The top 100 drugs: a 5-year outlook by therapeutic area, 2026–2031
$546bn of 2025 sales across 12 therapy areas, projected drug by drug with patent expiries, Medicare negotiated prices and new launches. See the method our ready-to-go reports use. Read the report →
Ready-to-go or built around your question
Ready-to-go
The standard report below, on any product in the catalogue. Fixed scope, fixed price, no scoping call.
- Global view plus EU5 and US detail
- Base, low and high scenarios, 2027–2031
- PDF report and Excel model
- Delivered in 5 business days
Portfolio pack
Five ready-to-go analyses ordered together: a therapy area, a competitor set or your own portfolio.
- Same standard scope per product
- One cross-product summary
- Delivered in 10 business days
Custom
Your markets, your question. For pipeline assets not yet approved, single-country deep-dives (Greece, Cyprus, the Balkans, any EU market), launch sequencing, in-licensing and deal screening.
- Scoping call and written proposal
- Your own scenarios and assumptions
- Timeline agreed in the proposal
The ready-to-go 5-year market analysis
- Executive summaryThe 5-year outlook in one page: peak-year range, key drivers and the risks that move it.
- Product and regulatory profileIndications, approvals and status in the EU and US, designations, label changes and exclusivity.
- Patient populationPrevalence, diagnosed and treated patients by market, from published epidemiology.
- Treatment landscapeStandard of care, guidelines and where the product sits in the treatment pathway.
- CompetitionMarketed competitors, late-stage pipeline, biosimilar and generic entry, and loss-of-exclusivity timing.
- Pricing and accessList-price and reimbursement context, HTA outcomes and access barriers by market.
- 5-year revenue scenariosBase, low and high cases for 2027–2031 by region, with uptake, share and price assumptions set out.
- Risks and catalystsUpcoming readouts, regulatory dates, patent events and policy changes that could change the forecast.
Sources: official regulator records (EMA, European Commission, FDA), company filings and reports, published literature and HTA decisions; each fact is referenced. Forecasts are modelled scenarios built on stated assumptions, not guarantees. Not investment advice.
Find your product
Every EU-authorised medicine in the EMA register and every FDA approval in our database. Not listed? Order it anyway: pipeline and unlisted products are covered as custom analyses.
2,527 products match.
| Product | Company | Therapeutic area | Market · date | |
|---|---|---|---|---|
| Deferiprone Lipomed deferiprone Generic | Lipomed GmbH | Iron Overload; beta-Thalassemia | 🇪🇺 EU 2018-09-19 | Order → |
| Hulio adalimumab Biosimilar | Biosimilar Collaborations Ireland Limited | Hidradenitis Suppurativa; Psoriasis; Uveitis; Arthritis, Rheumatoid; Spondylitis, Ankylosing; Crohn Disease; Colitis, Ulcerative; Arthritis, Psoriatic | 🇪🇺 EU 2018-09-17 | Order → |
| Ilumetri tildrakizumab | Almirall, S.A. | Psoriasis | 🇪🇺 EU 2018-09-17 | Order → |
| Nerlynx neratinib | Pierre Fabre Medicament | Breast Neoplasms | 🇪🇺 EU 2018-08-31 | Order → |
| Veyvondi vonicog alfa | Baxalta Innovations GmbH | von Willebrand Diseases | 🇪🇺 EU 2018-08-31 | Order → |
| Cablivi caplacizumab Orphan | Ablynx NV | Purpura, Thrombotic Thrombocytopenic | 🇪🇺 EU 2018-08-30 | Order → |
| Onpattro patisiran OrphanAccelerated assessmentAdditional monitoring | Alnylam Netherlands B.V. | Amyloidosis, Familial | 🇪🇺 EU 2018-08-27 | Order → |
| Ulipristal Acetate Gedeon Richter ulipristal acetate | Gedeon Richter Plc. | Leiomyoma | 🇪🇺 EU 2018-08-27 | Order → |
| Duzallo allopurinol;lesinurad Additional monitoring | Grunenthal GmbH | Gout | 🇪🇺 EU 2018-08-23 | Order → |
| Kymriah tisagenlecleucel OrphanPRIMEATMP | Novartis Europharm Limited | Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Large B-Cell, Diffuse | 🇪🇺 EU 2018-08-23 | Order → |
| Mepsevii vestronidase alfa OrphanExceptional circumstancesAdditional monitoring | Ultragenyx Germany GmbH | Mucopolysaccharidosis VII | 🇪🇺 EU 2018-08-23 | Order → |
| Vyxeos liposomal (previously Vyxeos) daunorubicin;cytarabine Orphan | Jazz Pharmaceuticals Ireland Limited | Leukemia, Myeloid, Acute | 🇪🇺 EU 2018-08-23 | Order → |
| Yescarta axicabtagene ciloleucel OrphanPRIMEATMP | Kite Pharma EU B.V. | Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse | 🇪🇺 EU 2018-08-23 | Order → |
| Myalepta metreleptin OrphanExceptional circumstancesAdditional monitoring | Chiesi Farmaceutici S.p.A. | Lipodystrophy, Familial Partial | 🇪🇺 EU 2018-07-30 | Order → |
| Aimovig erenumab | Novartis Europharm Limited | Migraine Disorders | 🇪🇺 EU 2018-07-26 | Order → |
| Halimatoz adalimumab BiosimilarAdditional monitoring | Sandoz GmbH | Hidradenitis Suppurativa; Psoriasis; Arthritis, Juvenile Rheumatoid; Uveitis; Arthritis, Rheumatoid; Spondylitis, Ankylosing; Arthritis, Psoriatic | 🇪🇺 EU 2018-07-26 | Order → |
| Hefiya adalimumab Biosimilar | Sandoz GmbH | Spondylitis, Ankylosing; Hidradenitis Suppurativa; Psoriasis; Arthritis, Juvenile Rheumatoid; Uveitis | 🇪🇺 EU 2018-07-26 | Order → |
| Hyrimoz adalimumab Biosimilar | Sandoz GmbH | Arthritis, Rheumatoid; Arthritis, Psoriatic; Spondylitis, Ankylosing; Uveitis; Hidradenitis Suppurativa; Colitis, Ulcerative; Arthritis, Juvenile Rheumatoid; Cr | 🇪🇺 EU 2018-07-26 | Order → |
| Nityr nitisinone Generic | Cycle Pharmaceuticals (Europe) Ltd | Tyrosinemias | 🇪🇺 EU 2018-07-26 | Order → |
| Rxulti brexpiprazole | Otsuka Pharmaceutical Netherlands B.V. | Schizophrenia | 🇪🇺 EU 2018-07-26 | Order → |
Order a report or brief us
We confirm scope and send the invoice by e-mail; work starts on confirmation.